Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014

M1 Kliniken AG: HAEMATO AG sells its 100% subsidiary HAEMATO Pharm GmbH to PHOENIX group

M1 Kliniken AG announces that its 85% subsidiary, HAEMATO AG, today signed an agreement for the sale of its wholly owned subsidiary HAEMATO Pharm GmbH to the PHOENIX group, one of Europe’s leading healthcare providers headquartered in Mannheim. The completion of the transaction remains subject to the customary antitrust approvals. The parties have agreed not to disclose the financial details of the transaction.

With this transaction, M1 Kliniken AG is consistently pursuing its strategic course to position itself as a globally leading, vertically integrated pure-play provider in the field of medical aesthetics.

Contact:
Attila Strauss, Management Board
Corporate Communications
E-Mail: ir@m1-kliniken.de

Press Release // October 16, 2025
 

Actor Pharmaceuticals and Megalabs become partners for the commercialization of Formycon’s Eylea^® biosimilar FYB203 (aflibercept) for Australia and Latin America
 

Planegg-Martinsried, Germany – Formycon AG (FSE: FYB, “Formycon”) announces that Klinge Biopharma GmbH (“Klinge”), the exclusive owner of the global commercialization rights of Formycon’s Eylea^®1 biosimilar FYB203 (aflibercept), concluded an exclusive license agreement with Actor Pharmaceuticals Pty. Ltd. (“Actor”) for the commercialization of FYB203 in Australia. Furthermore, for Latin America, Klinge has signed an exclusive license agreement with Megalabs S.A. (“Megalabs”).

Upon signature of the agreements, Klinge is eligible to receive upfront and milestone payments, plus royalties on net sales. Formycon will participate in the mid-single-digit to low-double-digit percentage range in all payment streams to Klinge resulting from these agreements. Furthermore, Formycon will act as authorized designee to organize the supply chain for FYB203 and will receive additional service payments and a volume-based profit component for organizing the commercial market supplyon behalf of Klinge.

“Severe retinopathies are on the rise worldwide due to demographic trends and the increasing number of diabetes cases, which can lead to retinal diseases. With the partnerships for Australia and Latin America, Klinge has laid the foundation for making our Eylea^® biosimilar FYB203 available as an effective and cost-efficient treatment option in further important regions of the world. With Actor and Megalabs, we have gained two strong distribution partners with excellent regional networks and a profound local market knowledge. Together, we are focused on improving the treatment options for the many patients who have been underserved in the past. At the same time, we are contributing to reduce the financial burden on healthcare systems,” says Nicola Mikulcik, Chief Business Officer (CBO) of Formycon AG.

Actor Pharmaceuticals is an established Australian pharmaceutical company specializing in the registration and commercialisation of innovative medicines and biosimilars in Australia. With a strong commitment to quality, patient access, and long-term partnerships, Actor Pharmaceuticals collaborates with global industry leaders to bring clinically proven therapies to the Australian market. The company’s expertise spans product registration, market access, and commercialization – driving growth across both prescription and over-the-counter segments.

Megalabs is a leading pharmaceutical company based in Uruguay with a strong presence and market position in the Americas. Megalabs is at the cutting edge of biotechnological innovation, with its High-Tech business unit serving as one of the main pillars of the organization’s success. The company’s various business areas also include the development, manufacturing and marketing of biosimilar products.

In June 2024, the aflibercept biosimilar FYB203 was approved by the US Food and Drug Administration (“FDA”). Approval by the European Commission followed in January 2025 and approval by the British MHRA one month later. For Australia, the regulatory application has been submitted to the Therapeutic Goods Administration (“TGA”). Formycon is also working closely with Megalabs to prepare the applications for approval in Latin American countries.²

Eylea^® (aflibercept) is used to treat neovascular age-related macular degeneration (nAMD) and other severe retinal diseases. The active ingredient inhibits the vascular endothelial growth factor (VEGF), which is responsible for the excessive formation of blood vessels in the retina.

———————–

¹⁾  Eylea^® is a registered trademark of Regeneron Pharmaceuticals Inc.

²⁾  The commercial launch of FYB203 in Australia and Latin America depends on several factors – firstly on approval by the respective regional regulatory authorities, and secondly on the progress and outcome of ongoing or potential future patent litigation or possible settlement agreements.

About Formycon:
Formycon AG (FSE: FYB) is a leading, independent developer of high-quality biosimilars, follow-on products of biopharmaceutical medicines. The company focuses on therapies in ophthalmology, immunology, immuno-oncology and other key disease areas, covering almost the entire value chain from technical development through clinical trials to approval by the regulatory authorities. For commercialization of its biosimilars, Formycon relies on strong, well-trusted and long-term partnerships worldwide. With FYB201/ranibizumab and FYB202/ustekinumab, Formycon already has two biosimilars on the market. Another biosimilar, FYB203/aflibercept, has been approved by the FDA, EMA, and MHRA. Four pipeline candidates are currently in development. With its biosimilars, Formycon is making an important contribution to providing as many patients as possible with access to highly effective and affordable medicines.

Formycon AG is headquartered in Munich, listed in the Prime Standard of the Frankfurt Stock Exchange: FYB / ISIN: DE000A1EWVY8 / WKN: A1EWVY and is part of the SDAX selection index. Further information can be found at: https://www.formycon.com/

About Biosimilars:
Since their introduction in the 1980s, biopharmaceutical drugs have revolutionized the treatment of serious and chronic diseases. By 2032, many of these drugs will lose their patent protection – including 45 blockbusters with an estimated total annual global turnover of more than 200 billion US dollars. Biosimilars are successor products to biopharmaceutical drugs for which market exclusivity has expired. They are approved in highly regulated markets such as the EU, the USA, Canada, Japan and Australia in accordance with strict regulatory procedures. Biosimilars create competition and thus give more patients access to biopharmaceutical therapies. At the same time, they reduce costs for healthcare systems. Global sales of biosimilars currently amount to around 21 billion US dollars. Analysts assume that sales could rise to over 74 billion US dollars by 2030.

About Actor Pharmaceuticals:
Actor Pharmaceuticals is a privately held pharmaceutical company dedicated to improving access to high-quality, clinically proven healthcare products across Australia and New Zealand. With a focus on trusted European brands, innovation, and patient well-being, Actor partners with global manufacturers to introduce and grow consumer and prescription health solutions in the region. Backed by deep industry expertise and a long-term vision, Actor Pharmaceuticals is committed to building enduring brands that make a meaningful difference in people’s lives.

About Megalabs:
Megalabs is a pharmaceutical company committed to providing healthcare professionals and consumers with affordable therapeutic solutions for a healthier and more fulfilling life. The company is present in 20 countries, with more than 8,000 collaborators, and offers more than 1,800 products that span all therapeutic areas. Its continuous growth is supported by 18 production plants, a highly diversified portfolio with more than 1,800 products, and 12 R&D centers. Megalabs is a forward-looking company with an established reputation as one of the leading pharmaceutical players in the Americas.

Contact:
Sabrina Müller
Director Investor Relations and Corporate Communications
Formycon AG
Fraunhoferstr. 15
82152 Martinsried/Planegg
Germany

phone +49 (0) 89 – 86 46 67 149
fax + 49 (0) 89 – 86 46 67 110
Sabrina.Mueller@formycon.com

Disclaimer:
This press release may contain forward-looking statements and information which are based on Formycon’s current expectations and certain assumptions. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, performance of the company, development of the products and the estimates given here. Such known and unknown risks and uncertainties comprise, among others, the research and development, the regulatory approval process, the timing of the actions of regulatory bodies and other governmental authorities, clinical results, changes in laws and regulations, product quality, patient safety, patent litigation, contractual risks and dependencies from third parties. With respect to pipeline products, Formycon AG does not provide any representation, warranties or any other guarantees that the products will receive the necessary regulatory approvals or that they will prove to be commercially exploitable and/or successful. Formycon AG assumes no obligation to update these forward-looking statements or to correct them in case of developments which differ from those anticipated. This document neither constitutes an offer to sell nor a solicitation of an offer to buy or subscribe for securities of Formycon AG. No public offering of securities of Formycon AG will be made nor is a public offering intended. This document and the information contained therein may not be distributed in or into the United States of America, Canada, Australia, Japan or any other jurisdictions, in which such offer or such solicitation would be prohibited. This document does not constitute an offer for the sale of securities in the United States.

Frauenfeld, 16 October 2025

Press release

DocMorris accelerates sequential Rx growth and increases non-Rx revenue

• Total revenue rises by 9.5 per cent in the first nine months
• Sequential Rx quarterly growth accelerates to 9.2 per cent in Q3
• Non-Rx business in Germany grows in all areas; TeleClinic up over 140 per cent
• Full roll-out of AI-based DocMorris health companion
• Andrea Skersies appointed CCO and member of the Executive Board

CEO Walter Hess says: “Our continuous growth shows that we are on the right track with marketing efficiency in our core business and the scaling of innovative services. With the new AI-based DocMorris Health Companion, we are using artificial intelligence for millions of customers and patients and making it a tangible experience. We are also strengthening our position as Europe’s trusted health brand. David Masó becomes new Chief AI Health Officer, and with Chief Commercial Officer Andrea Skersies, we are expanding the Group Executive Board with an experienced e-commerce expert.”

CFO Daniel Wüest adds: “DocMorris has made an encouraging start to what is traditionally its strongest fourth quarter. The figures for the first nine months confirm our growth trajectory: we have significantly increased both revenue and our customer base and are on track to achieve our 2025 outlook. In the third quarter, the focus was on sustainable, profitable and future sales growth while improving profitability through efficiency gains and cost reductions. This will enable us to lay the foundation for achieving our EBITDA breakeven target in the course of 2026.”

Significant revenue growth in the first nine months

• DocMorris increased its external revenue[1] by 9.5 per cent[2] to CHF 854.3 million in the first nine months 2025, despite the discontinuation of the Zur Rose brand in Germany at the end of 2024.
• In the third quarter, sales increased by 8.1 per cent to CHF 282.3 million, despite the usual seasonal slowdown due to the summer holidays.
• The Germany segment grew by 10.0 per cent in the first nine months, while revenue in the Europe segment increased by 2.7 per cent with a focus on profitability.
• The number of active customers[3] increased from 10.3 million to 10.6 million in the first nine months and from 10.5 million to 10.6 million in the third quarter.

Sequential Rx growth continues to accelerate

• External Rx revenue rose significantly by 37.9 per cent in the first nine months.
• Sequential Rx growth continued to accelerate: from the second to the third quarter, Rx revenue increased by 9.2 per cent.

Revenue increase across all non-Rx areas

• Non-Rx external revenue[4] increased by 4.3 per cent in the first nine months and also grew across all areas from the second to the third quarter.
• TeleClinic increased its revenue by more than 140 per cent to over CHF 17 million in the first nine months and is increasingly becoming an important part of the German business.
• TIME Magazine named TeleClinic one of the “World’s Top HealthTech Companies 2025”.
• Retail media and the marketplace achieved high double-digit growth.
• All service platforms are making a disproportionately large contribution to profitability.

DocMorris health companion available to all app users

• The AI-based DocMorris health companion has been available to all users of the DocMorris app since the beginning of October with the full rollout of the beta phase of the DocMorris Assistant.
• DocMorris is also strengthening the strategic importance of the AI-based health companion in organisational terms and consolidates the associated activities relating to the digital health ecosystem under Executive Board member David Masó as the new Chief AI Health Officer (CAHO).

Streamlining management structures and using AI to increase efficiency

• DocMorris is bundling all e-commerce activities in the Germany and Europe segments under Andrea Skersies as the new Chief Commercial Officer (CCO) and member of the Executive Board, while at the same time reducing one management level. Andrea Skersies has many years of management experience in online retail, including 13 years as Chief Marketing Officer (CMO) and member of the Executive Board at Zooplus and as CMO of an online pharmacy.
• As part of this realignment, further management structures will be adjusted and the organisation streamlined in a targeted manner.
• DocMorris is also reducing costs through the increased use of AI automation.

Outlook

• Management confirms the revenue and earnings guidance for 2025 communicated on 10 April, as well as EBITDA breakeven in the course of 2026 and free cash flow breakeven in the course of 2027. The other medium-term targets remain unchanged.

Investors and analyst contact
Dr. Daniel Grigat, Head of Investor Relations & Sustainability
Email: ir@docmorris.com, phone: +41 52 560 58 10

Media contact
Torben Bonnke, Director Communications
Email: media@docmorris.com, phone: +49 171 864 888 1

Agenda

DocMorris
The Swiss-based DocMorris AG is a leading company in the fields of online pharmacy, telemedicine and marketplace with strong brands in Germany and other European countries. Deliveries are mainly from the highly automated logistics centre in Heerlen, the Netherlands. TeleClinic is Germany’s largest telemedicine platform, connecting patients with more than 5,000 physicians. DocMorris operates leading marketplaces for health and personal care products in Southern Europe. With its broad range of products and services, DocMorris is pursuing its vision of becoming the leading digital health companion for everyone to manage their health in one click. Around 1,600 employees in Germany, the Netherlands, Spain, France, Portugal and Switzerland generated an external revenue of CHF 1,085 million serving more than10 million active customers in 2024. The shares of DocMorris AG are listed on the SIX Swiss Exchange (securities number 4261528, ISIN CH0042615283, ticker DOCM). For further information, please visit corporate.docmorris.com.

Disclaimer
This communication expressly or implicitly contains certain forward-looking statements concerning DocMorris AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of DocMorris AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. DocMorris AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

^[1] External revenue consists of the consolidated revenue of DocMorris plus online revenues of pharmacies supplied by DocMorris, less the consolidated revenue from supplying them.

^[2] All percentages are in local currency.

^[3] Customers supplied by DocMorris, either directly or through its partners.

^[4] Consisting of OTC business and services (TeleClinic, marketplace, retail media)

Ad-hoc notification in accordance with Sec. 17 of the MAR

Drägerwerk AG & Co. KGaA: Preliminary figures Q3 2025: Significant increase in net sales and earnings – upper half of forecast range expected

Lübeck, October 15, 2025 – Based on preliminary calculations, Dräger increased its net sales in the third quarter of 2025 by 10.1 percent (net of currency effects; nominal: 7.6 percent) to around EUR 833 million (Q3 2024: EUR 774.6 million). Both divisions recorded significant growth again after a decline in the prior year. The medical division saw an increase of 10.2 percent (net of currency effects; nominal: 7.3 percent) to around EUR 471 million (Q3 2024: EUR 439.1 million), while the safety division grew by 9.9 percent (net of currency effects; nominal: 7.9 percent) to around EUR 362 million (Q3 2024: EUR 335.5 million). The Group’s gross margin rose to around 45.6 percent (Q3 2024: 43.5 percent).

Earnings before interest and taxes (EBIT) increased to around EUR 57 million, more than doubling (Q3 2024: EUR 24.4 million). In the same quarter of the prior year, EBIT had been still supported by a positive one-off effect amounting to around EUR 10 million. The main reason for the good earnings performance in the third quarter of 2025 was the significant growth in net sales, while costs rose only moderately. The EBIT margin improved by 3.7 percentage points to 6.8 percent (Q3 2024: 3.1 percent).

Order intake rose by 6.9 percent in the third quarter (net of currency effects; nominal: 4.9 percent) to around EUR 856 million (Q3 2024: EUR 816.2 million). In the medical division, it increased by 5.4 percent (net of currency effects; nominal: 3.5 percent) to around EUR 485 million (Q3 2024: EUR 468.4 million) following a decline in the prior year. In the safety division, order intake grew by 8.8 percent (net of currency effects; nominal: 6.8 percent) to around EUR 371 million (Q3 2024: EUR 347.8 million).

Business performance in the first nine months of 2025
Order intake rose by 9.0 percent (net of currency effects; nominal: 7.2 percent) to around EUR 2,594 million in the first nine months. This not only exceeded the prior year’s high level (9 months 2024: EUR 2,420.5 million), but also reached the highest nine-month level since the record year of 2020. Both divisions contributed to this positive development: in the medical division, order intake increased significantly by 11.6 percent (net of currency effects; nominal: 9.3 percent) after a decline in the prior year to around EUR 1,496 million (9 months 2024: EUR 1,368.5 million); this was partly due to a major multi-year order from Mexico in the mid double-digit million euro range, which Dräger received in the second quarter. In safety division, order intake in the first nine months rose by 5.7 percent (net of currency effects; nominal: 4.4 percent) to around EUR 1,099 million (9 months 2024: EUR 1,052.1 million).

Net sales increased by 3.7 percent (net of currency effects; nominal: 2.1 percent) to around EUR 2,344 million (9 months 2024: EUR 2,295.1 million). Following a decline in the prior year, the medical division recorded growth of 4.7 percent (net of currency effects; nominal: 2.9 percent) to around EUR 1,322 million (9 months 2024: EUR 1,285.3 million). The safety division grew by 2.4 percent (net of currency effects; nominal: 1.1 percent) to around EUR 1,021 million (9 months 2024: EUR 1,009.7 million). The Group’s gross margin rose to around 45.1 percent (9 months 2024: 44.4 percent).

At around EUR 77 million, EBIT did not reach the prior year’s figure (9 months 2024: EUR 80.1 million), but this was mainly due to the positive one-off effects in the prior year: In the second quarter of 2024, Dräger sold a non-strategic business area in the Netherlands and a property in the U.S. for a total of around EUR 20 million in addition to the sale of a building in Spain for around EUR 10 million in the third quarter of 2024. These earnings contributions are now missing. Currency effects and customs duties also had a negative impact on earnings in the first nine months of 2025. The EBIT margin amounted to around 3.3 percent (9 months 2024: 3.5 percent).

Forecast for 2025: Net sales and EBIT margin expected to be rather in the upper half of the range
Due to the very good business performance and the continued high order intake, we now tend to expect net sales growth of 3.0 to 5.0 percent net of currency effects (previously 1.0 to 5.0 percent net of currency effects) and an EBIT margin of 4.5 to 6.5 percent (previously 3.5 to 6.5 percent).

The full results for the first nine months of the fiscal year will be published on October 29, 2025.

Drägerwerk AG & Co. KGaA
Moislinger Allee 53–55
23558 Lübeck, Germany
www.draeger.com

Investor Relations:
Thomas Fischler
Tel. +49 451 882-2685
thomas.fischler@draeger.com

Corporate Communications:
Melanie Kamann
Tel. +49 451 882-3998
melanie.kamann@draeger.com

Disclaimer
This ad hoc report contains statements on the future development of Dräger Group. These forward-looking statements are based on the current expectations, presumptions, and forecasts of the Executive Board as well as the information available to date. They were compiled to the best of the company’s knowledge. Dräger does not provide any warranty nor assume any responsibility for the future developments and results described above. These are dependent on a number of factors. They entail various risks and contingencies outside of the company’s influence and are based on assumptions which could prove to be incorrect. Dräger does not assume any responsibility for updating the forward-looking statements contained in this report. This does not infringe any legal stipulations on the adjustment of forecasts. Please go to Investor Relations / Definitions of financial indicators at www.draeger.com for information on alternative performance measures used.

Not for release, publication or distribution, directly or indirectly, in or into the United States of America, Australia, Canada or Japan or any other jurisdiction in which such release, publication or distribution would be unlawful. The important notes at the end of this announcement must be observed.

Berlin, 15 October 2025 – The Cabinet draft to amend the Medical Cannabis Act (MedCanG) triggered widespread media coverage last week—predominantly critical. The Federal Ministry of Health (BMG) plans to prohibit initial prescriptions of medical cannabis flowers via telemedicine and to introduce a ban on mail‑order dispensing of cannabis by pharmacies.

General‑interest and trade media have in some cases reacted sharply to the proposals. DIE ZEIT argues the measures target “the wrong people” and could significantly impede patient care.^[1] In Pharmazeutische Zeitung, the German Association of Mail‑Order Pharmacies calls the planned shipping ban “overshooting the mark” and is counting on corrections during the parliamentary process.^[2] DER SPIEGEL describes the BMG’s proposal as “nonsensical,” assuming that criminals would be the main beneficiaries of the planned changes.^[3] Dissent is also emerging within the governing coalition: Carmen Wegge, legal policy spokesperson of the SPD parliamentary group, and Dr. Christos Pantazis, the group’s health policy spokesperson, labelled the draft on Instagram as “not acceptable”—among other reasons because it discriminates against patient groups and violates European law. ^[4]

Medical cannabis is displacing the black market

“We welcome—and share—the widespread criticism from the media and policymakers of the planned legislative changes. As we set out in our statement this summer, the MedCanG in its current form undoubtedly has room for improvement,” says Philip Schetter, CEO of Cantourage. “And yet, over the past 18 months it has enabled hundreds of thousands of patients to begin cannabis therapy. Most of these people previously obtained cannabis on the black market—exactly where they would be pushed back if the BMG’s proposal were implemented, because otherwise there still is no functioning legal supply routes for cannabis. Criminals across Germany would be delighted. We are confident, however, that the upcoming parliamentary process will bring substantial changes to the BMG’s proposal.”

Committee and stakeholder hearings in parliament can, as experience shows, lead to substantive amendments to draft legislation—especially when, as is currently the case, legal and health‑policy objections have been raised. Moreover, the first interim report from the evaluation of the Cannabis Use Act (EKOCAN) reached the preliminary conclusion that there is currently no urgent need for action with respect to cannabis legalisation.^[5]

Also feeding into the process is an online petition currently before the German Bundestag calling for a halt to the planned changes to the medical cannabis law. With over 32,000 co‑signatures (as of 15 October 2025), the petition enjoys broad public support.^[6] Cantourage expressly supports the petition and calls on everyone to sign in order to prevent a resurgence of the cannabis black market in Germany.

Keep virtual first consultations and mail‑order dispensing possible

Philip Schetter demands: “A mandatory initial consultation between doctor and patient with clear quality standards is definitely a sensible legislative adjustment—there is broad consensus on this across the industry. However, it must also be possible to conduct this consultation virtually. At our in‑house telemedicine provider ‘Telecan’, this has always been standard practice and has proven itself in everyday care.”

Schetter, by contrast, calls for the complete deletion of the proposed pharmacy shipping ban: “Because of the wide range of strains and effect profiles, cannabis flower is a highly specialized field. Of the roughly 17,000 pharmacies in Germany, only a few hundred deal with the topic in any significant way—a shipping ban would make access to cannabis products virtually impossible for many people.”

Cantourage will further optimize its telemedicine offering “Telecan” over the coming months in anticipation of possible changes. The platform for cannabis therapies already meets all requirements of the German medical professional code of conduct for physicians and has seen an increase in new registrations since the planned legislative changes became known.

Cantourage will continue to closely monitor the legislative process and provide updates on the next steps.

Sources (all in German):
^[1]DIE ZEIT, „Kein Gras mehr im Sommerschlussverkauf“ (08.10.2025).
^[2]Pharmazeutische Zeitung, „Cannabis‑Versandverbot ‘nicht im Sinne der Apotheken’“ (09.10.2025).
^[3]DER SPIEGEL, „Der unsinnige Kampf gegen Gras auf Rezept“ (10.10.2025).
^[4]Carmen Wegge und Dr. Christos Pantazis on Instagram: „Kein Rückschritt bei Patient:innenrechten!“ (10.10.2025).
^[5]Universität Hamburg, „Evaluation des Konsumcannabisgesetzes (EKOCAN): 1. Zwischenbericht“ (29.09.2025).
^[6]Deutscher Bundestag, petition „Geplante Änderungen des medizinischen Cannabis-Gesetzes stoppen“.

About Cantourage
Cantourage is a leading European company for the production and distribution of medical cannabis. Cantourage enables growers worldwide to sell products in European medical markets. Founded in 2019, the company works with more than 60 cannabis growers from 18 countries. Cantourage ensures the highest pharmaceutical quality standards along the value chain and offers products in all relevant market segments: dried flowers, extracts, dronabinol and cannabidiol. The company has been listed on the Frankfurt Stock Exchange since November 11, 2022, under the ticker symbol “HIGH”.

Contact Investor Relation
ir@cantourage.com

This announcement does not constitute an offer to the public or a solicitation of anoffer to sell securities to the public, in particular not within the meaning of Regulation (EU) 2017/1129 (Prospectus Regulation).

Press Release

QUANTRO Therapeutics extends collaboration with Boehringer Ingelheim to address high unmet needs in cancer patients

• Extension of collaboration for two additional years follows successful completion of major high-throughput screening (HTS) campaign and identification of attractive hits for further development.
• The aim of the partnership is to develop first-in-class drug candidates targeting cancer-associated transcription factors.
• QUANTRO is eligible to receive success-based R&D, regulatory and commercial milestone payments up to an estimated total value of around € 500M.
• Company to attend BIO-Europe 2025 in Vienna, November 3–5.

Vienna, Austria, 14 October 2025: QUANTRO Therapeutics (QUANTRO), a technology leader in the discovery of first-in-class transcription factor targeting cancer treatments, is pleased to announce the extension of its strategic collaboration with Boehringer Ingelheim. Building on the progress made during the first phase, based on an agreement signed in 2022, this extension for two additional years will further advance the joint R&D program aiming to develop first-in-class drug candidates targeting cancer-associated transcription factors.

Cancer remains one of the leading causes of death worldwide, with a high unmet need for novel and effective treatments. Despite advancements in cancer therapy, many patients still face limited options and poor outcomes. This partnership aims to address these challenges by developing innovative therapeutics that target underlying mechanisms of cancer previously considered undruggable.

“We are excited to continue the successful collaboration with Boehringer Ingelheim to achieve our joint goal of transforming the lives of people living with cancer,” said Dr. Michael Bauer, CEO of QUANTRO. “The identification of functionally validated hits for difficult to drug transcription factor targets, using our HTS screening platform, confirms the precision, impact and maturity of our innovative time-resolved transcriptomics platform. We look forward to further pushing the boundaries of what is possible in transcriptomic drug discovery.”

Transcription factors are central regulators of gene expression and play a key role in the development and progression of cancer. Despite their relevance, they have remained largely inaccessible to drug development due to technical limitations and lacking precision of conventional assay techniques. These are incapable of adequately identifying direct transcriptional responses caused by drug treatments at early time-points, i.e. one hour after dosing. QUANTRO’s proprietary, time-resolved transcriptomics platform overcomes these limitations by enabling the precise characterization of transcriptional responses over time, thereby revealing actionable disease-driving mechanisms.

So far, Quantro has achieved technical proof-of-concept, cross-validation of its HTS screening technology, and the identification of functionally validated hits against previously undruggable transcription factors. This was followed by the successful completion of the company’s largest transcriptomic dual-target screening campaign to date, evaluating over 350,000 compounds to identify candidates specifically targeting selected transcription factors.

Now, QUANTRO will continue to apply its time-resolved transcriptomics platform to jointly advance the discovery of first-in-class small molecule inhibitors of selected oncogenic transcription factors.

Under the agreement with Boehringer Ingelheim, QUANTRO has already received payments and is eligible to receive further success-based R&D, regulatory and commercial milestone payments up to an estimated total value around € 500M. Further details of the collaboration terms were not disclosed.

QUANTRO retains full ownership of its technology platform and internal drug discovery programs targeting additional transcription factors beyond the scope of the collaboration.

Meet QUANTRO at BIO-Europe:

QUANTRO’s CEO Dr. Michael Bauer and Arianna Sabò, Head of R&D, will be attending BIO-Europe in Vienna from November 3–5, 2025 to engage with pharma partners and investors, showcasing the company’s latest progress with its transcriptomic drug discovery platform. Get in touch to schedule a meeting via the partnering system or through Contact | QUANTRO.

About QUANTRO:

QUANTRO Therapeutics is a transcriptomic Drug Discovery and R&D company focused on building a highly innovative pipeline of modulators, inhibitors or degraders of transcription factors, regulators of gene expression and cell signaling targets. QUANTRO’s transcriptomic discovery platform   uses a novel and proprietary time-resolved gene expression profiling technology to target gene transcription factors, so far considered un-druggable.

QUANTRO’s technology is uniquely positioned to quantify changes in gene expression over time with unprecedented precision and sensitivity, overcoming the deficiencies of traditional RT-qPCR based technologies like DRUG-seq, which are limited to only measure RNA abundance, without capturing information on transcriptional activity and dynamics.

QUANTRO was founded in 2019 as a spin-out from the prestigious research institutes IMBA and IMP in Vienna, Austria. Since 2020, the company has been supported by Boehringer Ingelheim Venture Fund (BIVF) and Evotec as seed investors, complemented by undisclosed proceeds from the ongoing strategic collaboration on selected oncology targets with Boehringer Ingelheim Oncology.

Please find more information on the website at www.quantro-tx.com or LinkedIn.

Contact
QUANTRO Therapeutics GmbH
Dr. Michael Bauer, CEO
Email: Contact | QUANTRO
Phone: +43 122 66001

Media Contacts
MC Services AG
Dr. Cora Kaiser, Dr. Johanna Kobler (international and German-speaking media inquiries)
Shaun Brown (international trade press)
Phone: +49 89 210228 0
Email: quantro@mc-services.eu

Together We Build: Rentschler Biopharma celebrates construction progress of new buffer media facility, largest single investment at Laupheim site

• Symbolic milestone for new buffer media station: Rentschler Biopharma underscores its commitment to the Laupheim headquarters and to the future of Germany and Europe as leading biotechnology hubs
• Shaping dialogue: Panel discussion held with members of the Executive Board and a representative of the NXTGN innovation platform on key industry topics, including international competitiveness, partnerships, and the business environment in Germany

Laupheim (Germany), October 13, 2025 – With a time capsule ceremony and panel discussion on October 10^th, Rentschler Biopharma SE celebrated the progress at its new buffer media station, which is currently under construction at the company’s headquarters in Laupheim. This project represents the largest single investment in the company’s history at the German site and marks an important contribution to strengthening the competitiveness of both Rentschler Biopharma and the biotechnology sector in Germany and Europe.

The highlight of the event was the symbolic placement of a time capsule at the new facility. It symbolizes Rentschler Biopharma’s commitment to scientific and technological progress and honors the contributions of employees and partners who made this milestone possible. The time capsule bears the message “Together We Build” – a symbol of shared responsibility for the future of healthcare. In a panel discussion, members of Rentschler Biopharma’s Executive Board, together with the Managing Director of the NXTGN Startup Factory, discussed how investments and innovation are shaping future viability and competitiveness in the biotech sector. Key topics included the attractiveness of Germany as a biotech hub and the importance of partnerships in driving innovation, competitiveness, and reliability of supply.

Benedikt von Braunmühl, Chief Executive Officer of Rentschler Biopharma, commented: “At Rentschler Biopharma, we invest with foresight in infrastructure that ensures stability and sustainable growth – always keeping in mind our clients and, above all, patients worldwide. The new buffer media station marks an important milestone in this regard and, as the largest single investment in our history at our headquarters, underscores our clear commitment to Laupheim as well as to Germany and Europe as leading biotech hubs. As an independent family-owned company, we have always taken a long-term, future-focused approach: We combine our strength in innovation with responsibility to ensure a sustainable future for Rentschler Biopharma. My sincere thanks go to all colleagues whose dedication and expertise have made this milestone possible.”

“Together We Build”: Celebrating construction progress with a time capsule ceremony and panel discussion

On October 10, 2025, Rentschler Biopharma celebrated the construction progress at the new buffer media station at its Laupheim headquarters with employees and guests, including politicians, business partners, and the press. A time capsule was placed in the new facility: Serving as a bridge between the present and a future full of potential, the robust steel box contained a sample of current buffer and media solutions, a rendering of the new building, messages from the site leadership in Laupheim and Milford (USA), and the company’s core values – a testament of its corporate culture. This tribute to the present was thus linked with a clear commitment to shaping the future.

Christiane Bardroff, Chief Operating Officer of Rentschler Biopharma, explained: “As a CDMO, it is our responsibility to support our global clients in transforming innovative ideas into life-saving biopharmaceuticals and enabling rapid market access for new therapies. With the new buffer media facility, we will be even better positioned to fulfill this responsibility: enhanced automation and digitalization will make our processes more efficient and secure, while providing employees with a state-of-the-art working environment. With additional capacity for buffer and media solutions, we are laying the foundation to respond flexibly to our clients’ growing needs while ensuring patients have reliable access to therapies.”

Dr. Michael Zyder, Managing Director of NXTGN, added: “Innovation requires reliability. Especially at a time when the future of Germany as a biotech hub is widely debated, the collaboration between Rentschler Biopharma and the NXTGN Startup Factory demonstrates what truly matters: a partnership of equals that connects novel ideas from research and start-ups with industrial implementation – strengthening Europe’s competitiveness and strategic sovereignty.”
 

About the new buffer media station

Buffer and media solutions are an essential foundation of biopharmaceutical production. By 2028, a new state-of-the-art buffer media station will be operational in Laupheim, located in a purpose-built four-story building covering 3,400 square meters. The facility will offer faster and more efficient processes, as well as ergonomically designed workstations, providing a modern working environment for employees. It will meet the highest automation and quality standards and, with its advanced equipment, will also contribute to Rentschler Biopharma’s environmental and sustainability goals.

Three media tanks and six buffer tanks will support the production of buffer and media solutions, with dedicated areas to meet the strictest hygiene and safety standards. In addition, the station will be connected to the in-house logistics system as well as to the piping systems for upstream and downstream processes within the existing infrastructure. The buffer media station is scheduled to become fully operational by 2028.

About Rentschler Biopharma SE

Rentschler Biopharma is a leading contract development and manufacturing organization (CDMO) focused exclusively on client projects. The company offers process development and manufacturing of biopharmaceuticals, as well as related consulting activities, project management and regulatory support. Rentschler Biopharma’s high quality is proven by its long-standing experience and excellence as a solution partner for its clients. A high-level quality management system, a well-established operational excellence philosophy and advanced technologies ensure product quality and productivity at each development and manufacturing step. Rentschler Biopharma is a family-owned company with about 1,400 employees, headquartered in Laupheim, Germany, with operations in Milford, MA, USA. In 2024, the company joined the United Nations Global Compact, emphasizing Rentschler Biopharma’s focus on sustainability. For further information about the company, please visit www.rentschler-biopharma.com. Follow Rentschler Biopharma on LinkedIn.

Contact:  

Rentschler Biopharma
Dr. Latika Bhonsle-Deeng
Global Head of Communications
Phone: +49-7392-701-467
communications@rentschler-biopharma.com

Media inquiries:

MC Services AG
Eva Bauer
Phone: +49-89-210228-0
rentschler@mc-services.eu

U.S.
Laurie Doyle
Phone: +1-339-832-0752
 

High-res pictures can be downloaded from our press section following this link: https://www.rentschler-biopharma.com/en-us/news-events/presskit/press-images/.

User name: Press
Password: press2025!